As biopharmaceutical pipelines expand and therapeutic modalities grow more complex, the demand for highly specific, reproducible, and customizable antibodies has never been greater. Two categories—post‑translational modification (PTM)–specific antibodies and anti‑idiotype (anti‑ID) antibodies—have become essential tools for both discovery research and regulated bioanalytical...